JP2011528913A5 - - Google Patents

Download PDF

Info

Publication number
JP2011528913A5
JP2011528913A5 JP2011520375A JP2011520375A JP2011528913A5 JP 2011528913 A5 JP2011528913 A5 JP 2011528913A5 JP 2011520375 A JP2011520375 A JP 2011520375A JP 2011520375 A JP2011520375 A JP 2011520375A JP 2011528913 A5 JP2011528913 A5 JP 2011528913A5
Authority
JP
Japan
Prior art keywords
mutant
factor
amino acid
acid substitution
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011520375A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011528913A (ja
JP6029826B2 (ja
Filing date
Publication date
Priority claimed from EP08013561A external-priority patent/EP2149603A1/en
Application filed filed Critical
Publication of JP2011528913A publication Critical patent/JP2011528913A/ja
Publication of JP2011528913A5 publication Critical patent/JP2011528913A5/ja
Application granted granted Critical
Publication of JP6029826B2 publication Critical patent/JP6029826B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011520375A 2008-07-28 2009-07-28 補因子の非存在下において凝固活性を有する第ｉｘ因子変異体および出血性疾患の処置のためのその使用 Expired - Fee Related JP6029826B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08013561.9 2008-07-28
EP08013561A EP2149603A1 (en) 2008-07-28 2008-07-28 Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
PCT/EP2009/005465 WO2010012451A1 (en) 2008-07-28 2009-07-28 Factor ix variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders

Publications (3)

Publication Number Publication Date
JP2011528913A JP2011528913A (ja) 2011-12-01
JP2011528913A5 true JP2011528913A5 (enExample) 2012-09-20
JP6029826B2 JP6029826B2 (ja) 2016-11-24

Family

ID=40032573

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011520375A Expired - Fee Related JP6029826B2 (ja) 2008-07-28 2009-07-28 補因子の非存在下において凝固活性を有する第ｉｘ因子変異体および出血性疾患の処置のためのその使用

Country Status (9)

Country Link
US (2) US10125357B2 (enExample)
EP (6) EP2149603A1 (enExample)
JP (1) JP6029826B2 (enExample)
KR (2) KR101947424B1 (enExample)
CN (1) CN102112608B (enExample)
AU (1) AU2009275391B2 (enExample)
CA (2) CA3033578C (enExample)
ES (3) ES2628688T3 (enExample)
WO (1) WO2010012451A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2985035T3 (es) 2008-09-15 2024-11-04 Uniqure Biopharma B V Mutante de polipéptido de factor IX, sus usos y su procedimiento de producción
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
AU2012222366A1 (en) 2011-03-02 2013-08-01 Novo Nordisk A/S Coagulation factor-targeting to TLT-1 on activated platelets
EA028914B1 (ru) * 2011-07-25 2018-01-31 Байоджен Хемофилия Инк. Исследования для мониторинга нарушений свертываемости крови
CN103173482A (zh) * 2011-12-22 2013-06-26 武汉科技大学 野生型和突变体hFⅨ毕赤酵母表达载体及构建方法和应用
EP2666782A1 (en) * 2012-05-22 2013-11-27 Imnate Sarl Coagulation factor VIII with reduced immunogenicity.
WO2014070349A1 (en) * 2012-10-29 2014-05-08 Regents Of The University Of Minnesota Factor ix variants
CN103060366A (zh) * 2012-12-25 2013-04-24 武汉科技大学 人凝血因子ⅸ突变体毕赤酵母表达载体及构建方法和应用
RS61387B2 (sr) 2013-02-15 2024-06-28 Bioverativ Therapeutics Inc Gen optimizovanog faktora viii
US9651567B2 (en) * 2013-05-14 2017-05-16 Cgt Enterprises, Llc Test strips for determining coagulation factor activities
EP2881463A1 (en) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
US11008561B2 (en) * 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
KR20180118659A (ko) 2016-02-01 2018-10-31 바이오버라티브 테라퓨틱스 인크. 최적화된 viii 인자 유전자
US11452749B2 (en) 2017-07-10 2022-09-27 Uniqure Ip B.V. Means and methods for AAV gene therapy in humans
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
GB201817810D0 (en) * 2018-10-31 2018-12-19 Ucl Business Plc Modified factor IX polypeptides
WO2020104480A1 (en) * 2018-11-19 2020-05-28 Uniqure Biopharma B.V. Adeno-associated virus vectors for expressing fviii mimetics and uses thereof
ES3062513T3 (en) * 2019-03-19 2026-04-13 CSL Innovation Pty Ltd Factor ix variants and uses thereof in therapy
CN110684798A (zh) * 2019-09-03 2020-01-14 深圳新诺微环生物科技有限公司 肌肉靶向的微环dna基因治疗
JP7803014B2 (ja) 2019-09-30 2026-01-21 バイオベラティブ セラピューティクス インコーポレイテッド レンチウイルスベクター製剤
JP2023537565A (ja) 2020-06-24 2023-09-04 バイオベラティブ セラピューティクス インコーポレイテッド タンパク質を発現するように改変されたレンチウイルスベクターの調製物から遊離第ｖｉｉｉ因子を除去する方法
CN114277057B (zh) * 2021-07-09 2023-10-13 上海天泽云泰生物医药有限公司 用于治疗或预防b型血友病的重组腺相关病毒载体和方法
KR20240099358A (ko) 2021-10-27 2024-06-28 리제너론 파마슈티칼스 인코포레이티드 B형 혈우병 치료를 위한 인자 ix를 발현하기 위한 조성물 및 방법
CN116590262A (zh) * 2023-03-23 2023-08-15 上海交通大学医学院附属瑞金医院 一种凝血因子ix突变体及其应用
US20250242056A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
WO1999003496A1 (en) * 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
DK1282438T3 (da) 2000-05-10 2005-11-14 Novo Nordisk Healthcare Ag Farmaceutisk sammensætning omfattende en faktor VIIa og en faktor XIII
RU2326126C2 (ru) * 2000-09-13 2008-06-10 Ново Нордиск Хелт Кэр Аг Полипептид фактора vii свертывания крови, его получение и применение
WO2002040544A2 (en) 2000-11-14 2002-05-23 Board Of Regents, University Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
RU2396347C2 (ru) * 2004-08-17 2010-08-10 Ксл Бехринг Гмбх Модифицированные витамин к-зависимые полипептиды
EP2423307A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IV polypeptides and use thereof for treatment
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
US8022187B2 (en) * 2007-02-01 2011-09-20 Baxter International Inc. FVIII-independent FIX-mutant proteins for hemophilia A treatment
EP2108045B1 (en) * 2007-02-01 2013-12-11 Baxter International Inc. Improved fix-mutant proteins for hemophilia b treatment
DE102008034724A1 (de) * 2008-07-25 2010-01-28 Alexander Koslow Verkugelungs- / Zerkleinerungsmaschine

Similar Documents

Publication Publication Date Title
Linden et al. Platelets: pleiotropic roles in atherogenesis and atherothrombosis
Schober et al. SDF-1α-mediated tissue repair by stem cells: a promising tool in cardiovascular medicine?
JP6002727B2 (ja) 末梢循環への骨髄由来多能性幹細胞動員薬
JP2012126750A5 (enExample)
JP5037331B2 (ja) 出血性障害の処置のための第ｉｘａ因子
EA029560B1 (ru) Применение химерного фактора свертывания крови для уменьшения ингибирующего иммунного ответа у субъекта
US20120164111A1 (en) Novel post-translational fibrinogen variants
JP2010530238A5 (enExample)
JP2003530093A5 (enExample)
EP2858659A1 (en) Procoagulant compounds
JP2014113157A5 (enExample)
JP2004180682A (ja) 改変第ＶＩＩＩ因子ｃＤＮＡおよびその誘導体
JP2017505114A5 (enExample)
ES2938890T3 (es) Proteínas de fusión de VWF glucosiladas con farmacocinética mejorada
WO2018042438A2 (en) Human blood-derived products having decreased fibrinolytic activity and uses thereof in hemostatic disorders
BR112015012854B1 (pt) Método para purificar proteínas selecionadas do grupo consistindo em plasminogênio, ativador do plasminogênio tecidual e outra(s) protease(s), solução compreendendo fibrinogênio e/ou fator viii e/ou vwf, seu uso e formulação farmacêutica
AU2007223880A1 (en) A method for the preparation of recombinant human thrombin and fibrinogen
JP2007521294A5 (enExample)
CN114929735A (zh) 因子viii构建体
EP1987063B1 (en) Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
Luyendyk et al. Factor XIII: driving (cross-) links in hemostasis, thrombosis, and disease
CN111770767A (zh) 用于从生物流体中去除纤溶蛋白的体外设备和基质、其方法和用途
JP2008545393A (ja) 進歩したインターフェロンαポリペプチド
WO2007101106A2 (en) Compositions and methods for modulating hemostasis using variant forms of activated factor v
ES2708675T3 (es) Mutante de GDF-5 para inducir la formación de cartílago